Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab plus chemotherapy in advanced biliary tract carcinoma
NCT04003636Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2019
- Primary completion
- Dec 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 24
01
Overview
A Phase 3 trial of pembrolizumab in biliary tract carcinoma (BTC), sponsored by Merck & Co.. Started Sep 2019; status: completed.
02
Drugs
03
Conditions
biliary tract carcinoma (BTC)
Beyond the preview
Go deeper on NCT04003636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04003636.